Recombinant therapies for infection and hyperproliferative...

Details Recombinant therapies for infection and hyperproliferative... Recombinant therapies for infection and hyperproliferative...

C - Chemistry, Metallurgy

12

N

C12N 15/86 (2006.01) A61K 48/00 (2006.01) C12N 15/54 (2006.01)

Patent

CA 2047363

Host cells may be treated for an infection or a hyperproliferation disorder which is characterized by the presence, in the affected cells, of a trans- acting factor capable of regulating gene expression by inserting into the cells a polynucleotide construct having a cis-acting regulatory sequence which is regulated by the trans-acting factor and an effector gene which renders said cell susceptible to protection or destruction. For example, the cis-acting region may be homologous to the HIV tar region, and the effector gene may encode ricin A or HSV-1 thymidine kinase. Upon infection with HIV, the HIV tat protein activates the tar region, and induces transcription and expression of ricin A, resulting in cell death, or of HSV-1 tk, resulting in cell death upon treatment with dideoxynucleotide agents such as acyclovir and gancyclovir.

Affiliated with

Also associated with

Rating

Recombinant therapies for infection and hyperproliferative... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant therapies for infection and hyperproliferative..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant therapies for infection and hyperproliferative... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1357855